# Qualification Criteria Reference - B.56 Programme

## mHSPC - Metastatic Hormone-Sensitive Prostate Cancer

### Apalutamide (mHSPC)

**All required:**
- [ ] Hormone-sensitive stage
- [ ] Documented metastases (bone scan or CT/MRI)
  - For lymph node-only: must be non-regional (above aortic bifurcation)
- [ ] ECOG 0-2
- [ ] Docetaxel completed OR physician decision to omit (documented rationale)
- [ ] No progression on ADT before program enrollment
- [ ] Prior radical treatment with ≤3 years adjuvant HT acceptable (if completed ≥1 year ago)
- [ ] Prior ADT for metastatic disease ≤6 months
- [ ] No prior abiraterone
- [ ] No bone-modifying agents (except for osteoporosis)

### Darolutamide + Docetaxel (mHSPC)

**All required:**
- [ ] Hormone-sensitive stage
- [ ] Documented metastases (bone scan or CT/MRI)
  - For lymph node-only: must be non-regional (above aortic bifurcation)
- [ ] ECOG 0-2
- [ ] Able to receive docetaxel (documented)
- [ ] No progression on ADT before program enrollment
- [ ] Prior radical treatment with ≤3 years adjuvant HT acceptable (if completed ≥1 year ago)
- [ ] Prior ADT for metastatic disease ≤6 months
- [ ] No prior abiraterone
- [ ] No bone-modifying agents (except for osteoporosis)

**Docetaxel Timing:** First of 6 cycles within 6 weeks of darolutamide start

### Enzalutamide (mHSPC)

**All required:**
- [ ] Hormone-sensitive stage
- [ ] Documented metastases (bone scan or CT/MRI)
  - For lymph node-only: must be non-regional (above aortic bifurcation)
- [ ] ECOG 0-2
- [ ] Docetaxel completed OR physician decision to omit (documented rationale)
- [ ] No progression on ADT before program enrollment
- [ ] Prior radical treatment with ≤3 years adjuvant HT acceptable (if completed ≥1 year ago)
- [ ] Prior ADT for metastatic disease ≤6 months
- [ ] No prior abiraterone
- [ ] No bone-modifying agents (except for osteoporosis)

---

## nmCRPC - Non-Metastatic Castration-Resistant Prostate Cancer

### Apalutamide / Darolutamide / Enzalutamide (nmCRPC)

**All required:**
- [ ] Castration-resistant: testosterone ≤50 ng/dL (≤1.7 nmol/L)
- [ ] PSA progression:
  - [ ] 3 consecutive rises
  - [ ] ≥1 week apart
  - [ ] 2 rises ≥50% above nadir
  - [ ] PSA >2 ng/mL
- [ ] M0 status confirmed:
  - [ ] Negative bone scan
  - [ ] CT/MRI or chest X-ray negative for distant metastases
  - [ ] Regional nodes only (below aortic bifurcation, <2 cm short axis) acceptable
- [ ] PSA doubling time ≤10 months
- [ ] ECOG 0-1
- [ ] No prior abiraterone

**Additional for Apalutamide/Enzalutamide:**
- [ ] No seizure history
- [ ] No seizure predisposing factors

---

## mCRPC - Metastatic Castration-Resistant Prostate Cancer

### Enzalutamide (mCRPC)

**Pre-docetaxel setting (chemo not clinically indicated):**
- [ ] Castration-resistant: testosterone ≤50 ng/dL (≤1.7 nmol/L)
- [ ] PSA progression OR radiological progression
- [ ] ECOG 0-1
- [ ] No prior abiraterone

**Post-docetaxel setting:**
- [ ] Castration-resistant: testosterone ≤50 ng/dL (≤1.7 nmol/L)
- [ ] PSA progression OR radiological progression
- [ ] ECOG 0-2
- [ ] No prior abiraterone

### Olaparib (mCRPC)

**All required:**
- [ ] Castration-resistant: testosterone ≤50 ng/dL (≤1.7 nmol/L)
- [ ] PSA progression OR radiological progression
- [ ] Progression on new-generation hormonal therapy
  - Prior docetaxel/cabazitaxel before or after hormonal therapy acceptable
- [ ] BRCA1 or BRCA2 pathogenic/likely pathogenic mutation (germline or somatic)
- [ ] ECOG 0-2
- [ ] CrCl >30 mL/min (reduce dose if 31-50 mL/min)

### Niraparib + Abiraterone (mCRPC)

**All required:**
- [ ] Castration-resistant: testosterone ≤50 ng/dL (≤1.7 nmol/L)
- [ ] PSA progression OR radiological progression
- [ ] No indication for chemotherapy in 1st line mCRPC
- [ ] BRCA1 or BRCA2 pathogenic/likely pathogenic mutation (germline or somatic)
- [ ] ECOG 0-2
- [ ] No prior abiraterone*
- [ ] No prior non-steroidal antiandrogen
- [ ] No prior PARP inhibitor
- [ ] CrCl >30 mL/min (reduce dose if 31-50 mL/min)

*Exception: May qualify if:
- Abiraterone started ≤4 months ago
- No progression observed during abiraterone
- No imaging required unless clinically indicated

**Critical:** Must use combination tablet (niraparib 100 mg + abiraterone 500 mg). Separate tablets NOT permitted.

### Talazoparib + Enzalutamide (mCRPC)

**All required:**
- [ ] Castration-resistant: testosterone ≤50 ng/dL (≤1.7 nmol/L)
- [ ] PSA progression OR radiological progression
- [ ] No indication for chemotherapy in 1st line mCRPC
- [ ] HRR gene pathogenic/likely pathogenic mutation (germline or somatic):
  - BRCA2, ATM, CDK12, CHEK2, BRCA1, PALB2, RAD51C
- [ ] ECOG 0-2
- [ ] No prior abiraterone
- [ ] No prior non-steroidal antiandrogen
- [ ] No prior PARP inhibitor
- [ ] CrCl >30 mL/min (reduce dose if 31-50 mL/min)

---

## Drug Interaction Rules

### Prohibited Combinations
- New-generation hormonal agents + docetaxel (except darolutamide in mHSPC)
- New-generation hormonal agents + other antiandrogens
- New-generation hormonal agents + CYP17 inhibitors

### Sequential Limitations
- Only ONE new-generation hormonal therapy line
- Only ONE PARP inhibitor line
- One-time use of both categories (antiandrogen + PARP inhibitor) permitted

---

## Continuation Patients

Patients previously treated with program drugs via other funding mechanisms (excluding ongoing clinical trials) may qualify if:
- Met original qualification criteria at treatment start
- Continue to meet ongoing treatment criteria
- Have documentation of original qualification
